
Highlights
Age Groups Seen
- Young Adult 18-25
- Adult 26-64
- Older Adult 65+
Languages
- English
In-Network Plans
View All Accepted Plans (12)Gender
MaleJohns Hopkins Affiliations:
- Johns Hopkins School of Medicine Faculty
About Mark Yarchoan
Primary Academic Title
Associate Professor of Oncology
Johns Hopkins Physician
Background
Dr. Mark Yarchoan
is a physician–scientist based in Baltimore who specializes in the treatment and study of gastrointestinal cancers, with a particular focus on liver malignancies, including hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA).
He received his undergraduate degree from Amherst College and his medical degree from the Perelman School of Medicine at the University of Pennsylvania. He completed his residency in internal medicine at the Hospital of the University of Pennsylvania, followed by a fellowship in medical oncology at the Johns Hopkins University School of Medicine, where he joined the faculty in 2018.
Dr. Yarchoan leads a research laboratory dedicated to developing novel immunotherapies for liver cancers. His translational research program integrates analyses of clinical trial biospecimens with preclinical modeling to identify and overcome barriers to effective antitumor immunity. A major focus of his work is the development of therapeutic cancer vaccines for hepatobiliary malignancies.
He serves as Principal Investigator on multiple clinical trials for hepatobiliary cancers, contributes to international guideline committees for liver cancer, and is a member of the Johns Hopkins Graduate Training Programs in Cellular and Molecular Medicine and Immunology.
Dr. Yarchoan’s contributions have been recognized with numerous honors, including the ASCO Young Investigator Award, the Conquer Cancer Foundation Career Development Award, the Mark R. Clements Award from the Cholangiocarcinoma Foundation, and the Blue Faery Award for Excellence in Liver Cancer Research.
Centers and Institutes
X Profile
Clinical Trial Keywords
Hepatocellular Carcinoma (HCC); Biliary tract cancer (BTC); Cholangiocarcinoma; Liver Cancer; Immunotherapy; Fibrolamellar hepatocellular carcinoma (FLC)
Clinical Trials Summary
DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Fibrolamellar Hepatocellular Carcinoma Fibrolamellar Hepatocellular Carcinoma (FLC)
A study of perioperative nivolumab with or without relatlimab in patients with resectable hepatocellular carcinoma (HCC). Role: PI
Find a Clinical Trial
View all trials by this principal investigator.
Research Interests
Dr. Mark Yarchoan is a physician-scientist specializing in translational cancer immunotherapy research for liver cancers. A major focus of his research is on the development of therapeutic cancer vaccines.
Research Summary
The Yarchoan Laboratory develops novel immunotherapies for the treatment of cancer, with a particular focus on liver cancers. Dr. Yarchoan’s research program integrates biospecimen analysis from clinical trials with mechanistic studies in preclinical models to identify and overcome barriers to effective antitumor immunity. His group also directs the Johns Hopkins Immunotherapy Biobank, a pan-cancer effort that has enabled key discoveries into biomarkers of response and immune-related toxicities from immune checkpoint therapy. The prior work from his group contributed to the development of tumor mutational burden (TMB) as a biomarker of response to PD-1 blockade and identified cytokine pathways, including IL-6, associated with immune-related toxicity. A major focus of ongoing work is the development of therapeutic cancer vaccines, including an "off-the-shelf" vaccine targeting the DNAJB1–PRKACA fusion in fibrolamellar HCC (FLC) and a personalized vaccine for HCC. Dr. Yarchoan’s research has been published in The New England Journal of Medicine, Nature Cancer, Nature Medicine, Nature Immunology, Journal of Clinical Investigation, and Hepatology.
Google Scholar - Publications
https://scholar.google.com/citations?user=iw1kBoAAAAAJ&hl=en
PubMed - Publications
http://www.ncbi.nlm.nih.gov/myncbi/browse/collection/46440227/
Selected Publications
-
Yarchoan M, Hopkins A, Jaffee EM (2017) Tumor Mutational Burden and Response Rate to PD-1 Inhibition. New England Journal of Medice 377: 2500–2501. PMCID: PMC6549688
-
Ho WJ, Zhu Q, Durham J, Popovic A, Xavier S, Leatherman J, Mohan A, Mo G, Zhang S, Gross N, Charmsaz S, Lin D, Quong D, Wilt B, Kamel IR, Weiss M, Philosophe B, Burkhart R, Burns WR, Shubert C, Ejaz A, He J, Deshpande A, Danilova L, Stein-O’Brien G, Sugar EA, Laheru DA, Anders RA, Fertig EJ, Jaffee EM, Yarchoan M. Neoadjuvant cabozantinib and nivolumab convert locally advanced hepatocellular carcinoma into resectable disease with enhanced antitumor immunity. Nature Cancer 2021 Jul 29;1–13
-
Yarchoan M, Gane EJ, Marron TU, Perales-Linares R, Yan J, Cooch N, Shu DH, Fertig EJ, Kagohara LT, Bartha G, Northcott J, Lyle J, Rochestie S, Peters J, Connor JT, Jaffee EM, Csiki I, Weiner DB, Perales-Puchalt A, Sardesai NY. Personalized neoantigen vaccine and pembrolizumab in advanced hepatocellular carcinoma: a phase 1/2 trial. Nature Medicine 2024 Apr;30(4):1044–1053. PMCID: PMC11031401
-
Kao CJ, Charmsaz S, Alden SL, Brancati M, Li HL, Balaji A, Munjal K, Howe K, Mitchell S, Leatherman J, Griffin E, Nakazawa M, Tsai HL, Danilova L, Thoburn C, Gizzi J, Gross NE, Hernandez A, Coyne EM, Shin SM, Babu JS, Apostol GW, Durham J, Christmas BJ, Konig MF, Lipson EJ, Naidoo J, Cappelli LC, Pabani A, Ged Y, Baretti M, Brahmer J, Hoffman-Censits J, Seiwert TY, Garonce-Hediger R, Guha A, Bansal S, Tang L, Jaffee EM, Chandler GS, Mohindra R, Ho WJ, Yarchoan M. Immune-related events in individuals with solid tumors on immunotherapy associate with Th17 and Th2 signatures. Journal of Clinical Investigation. 2024 Aug 29;134(20):e176567. PMCID: PMC11473156
-
Shu DH, Ho WJ, Kagohara LT, Girgis A, Shin SM, Danilova L, Lee JW, Sidiropoulos DN, Mitchell S, Munjal K, Howe K, Bendinelli KJ, Kartalia E, Qi H, Mo G, Montagne J, Leatherman JM, Lopez-Vidal TY, Zhu Q, Huff AL, Yuan X, Hernandez A, Coyne EM, Zaidi N, Zabransky DJ, Engle LL, Ogurtsova A, Baretti M, Laheru D, Durham JN, Wang H, Sunshine JC, Johnston RJ, Deutsch JS, Taube JM, Anders RA, Jaffee EM, Fertig EJ*, Yarchoan M*. Immunotherapy response induces divergent tertiary lymphoid structure morphologies in hepatocellular carcinoma. Nature Immunology. 2024 Nov;25(11):2110–2123. PMID: 39455893
Honors
- ASCO Career Development Award, Conquer Cancer Foundation/ASCO, 7/1/21
- Cholangiocarcinoma Foundation Mark R. Clements Award, Cholangiocarcinoma Foundation, 7/1/21
- Director's Teaching Award in Clinical Science, 1/1/19
- Incyte Young Investigator Award for Translational Science, 1/1/19
- ASCO Young Investigator Award, Conquer Cancer Foundation, 7/1/17
- Inaugural Linda Rubin Fellowship Recipient, Johns Hopkins, 1/1/17
Graduate Program Affiliations
Member, Graduate Training Program in Cellular and Molecular Medicine
Member, Graduate Training Program in Immunology
Locations
- Skip Viragh Outpatient Cancer Center
- 201 North Broadway Street, Viragh BLDG 5th FL, Baltimore, MD 21287
- Get Directions
- phone: 410-955-8964
- fax: 410-367-2194
Expertise
Education
- Fellowship: Johns Hopkins University School of Medicine, Medical Oncology, 2018
- Residency: Hospital of the University of Pennsylvania , Internal Medicine, 2015
- Medical Education: University of Pennsylvania School of Medicine, MD, 2012
Insurance
- Aetna
- CareFirst
- Cigna
- First Health
- Geisinger Health Plan
- HealthSmart/Accel
- Johns Hopkins Health Plans
- MultiPlan
- Pennsylvania's Preferred Health Networks (PPHN)
- Point Comfort Underwriters
- Private Healthcare Systems (PHCS)
- Veteran Affairs Community Care Network (Optum-VACCN)
Ratings & Reviews
4.9 out of 5
73 ratings, 39 reviewsThe Patient Rating score is an average of all responses to physician related questions on the national CG-CAHPS Medical Practice patient experience survey through Press Ganey. Responses are measured on a scale of 1 to 5, with 5 being the best score. Comments are also gathered from our CG-CAHPS Medical Practice Survey through Press Ganey and displayed in their entirety. Patients are de-identified for confidentiality and patient privacy.
- 5 out of 5 starsReviewed on 3/3/2026
Dr yarchoan is in my opinion the best dr for my condition. He truly makes me feel comfortable asking any questions. I feel like he gives me the best chance that I have to live.i feel blessed to have him as my dr.
- 5 out of 5 starsReviewed on 3/3/2026
Dr. Mark promotes trust and competency which as a cancer patient/survivor is incredibly important. He probably rates as one of the best doctors I've ever had experience with. He's brilliant he's sociable and he's a great communicator. I've seen him every 3 to 6 months for probably three years and it's been a pleasure.
- 4 out of 5 starsReviewed on 2/24/2026
Best ever
- 5 out of 5 starsReviewed on 2/24/2026
Brilliant and I think he really sees me.
- 5 out of 5 starsReviewed on 2/10/2026
Dr. Mark Yarchoan is outstanding. He's a compassionate and very knowledgeable doctor. Thanks to his care, I feel more optimistic about dealing with my liver cancer tumor. I can't imagine a better doctor than Mark Yarchoan.
- 5 out of 5 starsReviewed on 2/10/2026
Excellent - Dr. Yarchoan and his team have saved my life and I can't speak highly enough about them.
- 5 out of 5 starsReviewed on 2/10/2026
Wish there were more people like him
- 5 out of 5 starsReviewed on 1/27/2026
Dr. Yarchoan is brilliant. He's also keeping me alive and pain free.
- 5 out of 5 starsReviewed on 1/20/2026
He is exceptional
- 5 out of 5 starsReviewed on 1/13/2026
Dr Yarchoan and his team ([staff] and [staff]) are excellent. They have always been so friendly, caring, very supportive and attentive. They are excellent listeners. They are extremely knowledgeable, especially Dr Yarchoan. I'm so very grateful I found them.
- 5 out of 5 starsReviewed on 1/13/2026
Most compassionate caring and brilliant provider I have ever had
- 5 out of 5 starsReviewed on 1/7/2026
Dr Mark Yarchoan is a very remarkable doctor, he is patience, as we have the whole family of 4 in this visit, he answered all our questions patiently. Explaining the sickness clearly with the Image also, so we can understand more about the disease. He explained clearly about the coming treatments so we understand what's going on. I told him we live far away from Johns Hopkins but I like to be under his care.
- 5 out of 5 starsReviewed on 12/23/2025
Dr. Yarchoan is always accessible, easy to understand and empathetic regarding side effects.
- 5 out of 5 starsReviewed on 12/23/2025
Dr. Yarchoan is a lead investigating doctor in a trial drug. TTI-101.
- 5 out of 5 starsReviewed on 12/16/2025
Dr. Yarchoan and his team are the best I've ever encountered. Dr. Yarchoan has kept me alive (cancer) for the past year at least, and beyond what any of my other doctors expected. We always speak very highly of Dr. Yarchoan and trust his decisions about my care. I recommend him to everyone who needs the type of services he provides. His bedside manor is impeccable and I would go nowhere else.
- 5 out of 5 starsReviewed on 12/2/2025
I could not ask for a better provider than, Dr. Yarchoan. His care, concern and commitment to my case has far exceeded what I could have ever hoped for. I feel he has gone above and beyond to make sure I understood thoroughly what was going on, what the options were, and what his plan of care was for me. While no one ever wants to need to see an oncologist, I am grateful to be under his care and think he is not only a wonderful physician, but also a good human being.
- 5 out of 5 starsReviewed on 12/2/2025
We love Dr Yarchoan, he's so attentive, friendly and knowledgeable.
- 5 out of 5 starsReviewed on 11/25/2025
Excellent caring physician
- 5 out of 5 starsReviewed on 11/18/2025
He is exceptionally kind patient and takes the time to really explain in great detail anything applicable to my case. He's a great listener and explains his strategy and partners with me and my team.
- 5 out of 5 starsReviewed on 11/18/2025
Dr. Yarchoan is keeping me alive. I have advanced liver cancer.
- 5 out of 5 starsReviewed on 11/18/2025
Very considerate about coordinating and scheduling the visits. Provided information and answered questions in a way I could understand.
- 5 out of 5 starsReviewed on 10/21/2025
GREAT! COULDN''T. ASK FOR ANY BETTER!9..?
- 5 out of 5 starsReviewed on 10/14/2025
Dr. Yarchoan is very kind, knowledgeable and genuinely has cared about me and my health. He took time to explain everything so I understood what was going on and what next steps are!
- 5 out of 5 starsReviewed on 10/14/2025
He was patient, kind and respectful in addition to being very thoughtful, strategic and knowledgeable.
- 5 out of 5 starsReviewed on 10/7/2025
The very best hands down !
- 5 out of 5 starsReviewed on 10/7/2025
The best of the best
- 5 out of 5 starsReviewed on 9/30/2025
Mark Yarchoan is great.
- 5 out of 5 starsReviewed on 9/24/2025
Only one visit, but very knowledgeable.
- 5 out of 5 starsReviewed on 9/9/2025
Dr. Mark Yarchoan is an important asset to Johns Hopkins. He demonstrates an extraordinary amount of concern to ensure I am getting the best and most up-to-date medical care possible. He shows compassion and makes sure I understand exactly where I am on the treatment plan. By his demeanor, I know he does everything in his power to see that I survive this horrible diagnosis.
- 5 out of 5 starsReviewed on 8/26/2025
Dr. Yarchoan Is an amazing physician! My entire family have full faith and trust in his decisions and plans to take care of my cancer ad he has not let me down in any way.
- 5 out of 5 starsReviewed on 8/12/2025
Excellent doctors and I can tell he cares. Everyone at JH has been excellent. Thank you.
- 5 out of 5 starsReviewed on 8/5/2025
Excellant
- 5 out of 5 starsReviewed on 7/22/2025
Doing good job.
- 5 out of 5 starsReviewed on 7/15/2025
just one heck of a doctor
- 5 out of 5 starsReviewed on 6/3/2025
Dr. Yarchoan always shows utmost concern for my well being. He goes above and beyond to ensure I'm receiving all treatments, scans, etc. That will ensure the best possible outcomes. His positive attitude always gives me hope and his medical expertise is beyond reproach. Without his diligence to find a treatment that worked for me, I truly believe that I would not be alive today. He's very thorough and picks up on even the smallest detail that could, if left untreated, adversely affect my overall recovery. I thank God everyday that he's my oncologist.
- 5 out of 5 starsReviewed on 5/13/2025
Dr Yarchoan is the best of the best. His medical knowledge, his explanations and care and concern for his patients
- 5 out of 5 starsReviewed on 4/30/2025
Dr yarchoan spent time going over my case with me and my daughter and explained everything so that we could understand. He was really awesome.
- 5 out of 5 starsReviewed on 4/22/2025
Provider best ever
- 5 out of 5 starsReviewed on 4/22/2025
The best